// App-Quantinova.ai

e21108 : Financial impact of tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer bearing METex14 skipping in the United States.

Researchers

Presenter

  • Matthew Stargardter

Principal Investigators

  • Mo Yang

  • Jon Tosh

  • Apoorva Ambavane

  • Madhav Mittal

  • Helene Vioix

  • Frank Xiaoqing Liu

  • Ali McBride

Medical Centers

  • Evidera, Bethesda, MD

  • EMD Serono, Rockland, MD

  • Evidera, Inc., London, United Kingdom

  • Evidera, London, UK

  • QH, United Kingdom

  • Evidera, Gurgaon, Haryana, India

  • Merck KGaA, Darmstadt, Germany

  • University of Arizona Cancer Center, Tucson, AZ

Locations

  • United States

  • United Kingdom

  • India

  • Germany

Companies

  • EMD Serono Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Vascular endothelial growth factor A

Drug/Treatment

  • Capmatinib

  • Crizotinib

  • Tepotinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved